enzalutamide

mechanistic target of rapamycin kinase ; Homo sapiens







7 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35363301 Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. 2022 Jun 1 1
2 34439125 ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer. 2021 Aug 5 1
3 31967357 Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. 2020 Apr 3
4 32042320 Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. 2020 2
5 32205016 A phase I dose-escalation study of enzalutamide in combination with theĀ AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. 2020 May 1
6 29220539 Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. 2018 Jun 1
7 26712685 Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. 2016 Jun 1 1